Osteoporosis Treatment and Prevention: World Drug Market Forecast 2014-2024 & Future Prospects for Leading Companies

世界の骨粗しょう症治療・予防市場予測:抗嘔吐薬、骨粗しょう症治療薬、再吸収阻害薬、同化薬

◆タイトル:Osteoporosis Treatment and Prevention: World Drug Market Forecast 2014-2024 & Future Prospects for Leading Companies
◆商品コード:VISG409054
◆調査・発行会社:visiongain
◆発行日:2014年5月
◆ページ数:217
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single user licence(1名使用)GBP1,799 ⇒換算¥269,850見積依頼/購入/質問フォーム
Dept Licence(部署内共有可)GBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site Licence(同一国内社内共有可)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"世界の骨粗しょう症治療・予防市場予測:抗嘔吐薬、骨粗しょう症治療薬、再吸収阻害薬、同化薬"について調査・分析し、エグゼクティブサマリー、市場動向、世界市場規模・市場予測、地域別市場分析、主要国別市場分析、市場環境分析、専門家の見解、主要企業分析、結論などの情報をお届けいたします。

Osteoporosis drugs – new study showing you trends, R&D progress, and predicted revenues
Where’s the osteoporosis drugs market heading? Visiongain’s brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our 217-page report provides 132 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing pharma market.

Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT, PESTEL and Porter’s Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
- Dr. Karl Grindulis, Consultant Rheumatologist, Sandwell General Hospital, West Bromwich, UK
- Dr. Matthew Drake, Consultant in the Department of Medicine, Division of Endocrinology, Mayo Clinic Rochester, Minnesota, US

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you see forecasts to 2024 for these three submarkets and their respective segments:
• Antiresorptive Drugs
- Bisphosphonates
- Selective Oestrogen Receptor Modulators (SERMs)
- RANKL Antibodies
- Cathepsin K Inhibitors
- Other antiresorptive drugs
• Anabolic Drugs
- Human Recombinant Parathyroid Hormones
- Anti-Sclerostin monoclonal antibodies
• Other osteoporosis treatments

Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for products
How will leading drugs perform to 2024 at world level? Our study forecasts sales of 10 products, including these:
• Forteo
• Evista
• Prolia
• Actonel/Atelvia
• Fosamax
• Reclast/Aclasta
• Boniva

Our study also provides sales forecasts to 2024 for the following drugs which are currently in development:
• Duavee
• Odanacatib
• Romosozumab

Discover how high revenues can go. You will see what’s happening, understanding trends, challenges and opportunities.

Our analysis also breaks the main world forecast into geographical markets.

What are the prospects in the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for 12 national markets to 2024:
• US
• Japan
• China
• Germany
• France
• UK
• Italy
• Spain
• India
• Brazil
• Russia
• South Korea
• Rest of the World

There will be growth in established pharma markets and in developing countries. Our analyses show that India, Brazil, China, Russia and South Korea in particular, will continue to achieve high revenue growth to 2024. Developments worldwide in product approval and pricing will influence the market.

Leading companies and potential for market growth
Overall world revenue for osteoporosis drugs will reach $8.36bn in 2014, our work forecasts. We predict steady revenue growth from 2014 to 2024. Rising demand for osteoporosis drugs, expanding healthcare coverage, and the success of biological drugs will increase sales to 2024.

Our work shows you what organisations hold greatest potential. See profiles of 8 leading companies, including these:
• Eli Lilly
• Amgen
• GSK
• Merck
• Pfizer
• Novartis
• Sanofi
• Actavis

【レポートの目次】

1. Executive Summary
1.1 The Global Osteoporosis Drug Market Review
1.2 The Global Osteoporosis Drug Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Introduction to Osteoporosis
2.1 Osteoporosis Prevalence and Incidence, 2014
2.2 Osteoporosis: The Silent Killer
2.3 Osteoblasts are Critical in Bone Healing
2.4 Classifying Osteoporosis by Types
2.5 Classifying Osteoporosis by Treatments
2.5.1 Antiresorptive Medication
2.5.2 Anabolic Medication
2.6 Osteoporosis Risk Factors

3. The Global Osteoporosis Drug Market, 2014-2024
3.1 Scope of this Report
3.2 The Global Osteoporosis Drug Market in 2013
3.3 The Global Osteoporosis Drug Market: Sales Forecast 2014-2024
3.4 Breakdown of the World Osteoporosis Drug Market by Therapeutic Classes, 2013
3.5 The Global Osteoporosis Drug Market by Therapeutic Classes: Sales Forecast 2014-2024
3.6 Breakdown of the World Osteoporosis Drug Market by Leading Drugs, 2013
3.6.1 The Global Osteoporosis Drug Market by Leading Drugs: Sales Forecast 2014-2024
3.7 Which Osteoporosis Drugs Will Lead the Market in 2024?
3.7.1 Osteoporosis Products Pipeline, 2014
3.7.2 Forteo (Teriparatide) -Eli Lilly, 2014
3.7.3 Evista(Raloxifene) – Eli Lilly, 2014
3.7.4 Prolia (Denosumab) – Amgen, GSK and Daiichi Sankyo, 2014
3.7.5 Actonel/Atelvia (Risendronate) -Sanofi, Actavis, Ajinomoto Pharmaceuticals and Eisai, 2014
3.7.6 Fosamax (Alendronate) – Merck, 2014
3.7.7 Reclast/Aclasta (Zoledronic Acid) – Novartis, 2014
3.7.8 Boniva (Ibandronate) –Roche and GSK, 2014
3.7.9 Duavee (Bazedoxifene/Conjugated Estrogens) – Pfizer and Ligand Pharmaceuticals, 2014
3.7.10 Odanacatib (MK 0822) – Merck, 2014
3.7.11 Romosozumab (AMG 785) – Amgen and UCB, 2014
3.7.12 The Global Osteoporosis Drug Market: Drivers and Restraints 2014-2024

4. Leading National Osteoporosis Drug Markets, 2014-2024
4.1 Regional Breakdown of the World Osteoporosis Drug Market, 2013
4.2 Regional Breakdown of the World Osteoporosis Drug Market: Sales Forecast by Region, 2014-2024
4.3 How Will Regional Market Shares Change to 2024?
4.4 The US Osteoporosis Drug Market, 2013
4.4.1 The US Osteoporosis Drug Market: Forecast 2014-2024
4.5 Reimbursement Situation in the US, 2014
4.5.1 The US Keeps Dominating the Osteoporosis Drug Market: What About Healthcare Coverage?
4.6 The US Osteoporosis Drug Market: Drivers and Restraints, 2014-2024
4.7 The Leading European Osteoporosis Drug Markets, 2013
4.7.1 The Leading European Osteoporosis Drug Markets: Forecasts 2014-2024
4.7.2 The German Osteoporosis Drug Market Forecast, 2014-2024
4.7.3 The French Osteoporosis Drug Market Forecast, 2014-2024
4.7.4 The UK Osteoporosis Drug Market Forecast, 2014-2024
4.7.5 The Italian Osteoporosis Drug Market Forecast, 2014-2024
4.7.6 The Spanish Osteoporosis Drug Market Forecast, 2014-2024
4.8 The Japanese Osteoporosis Drug Market, 2013
4.8.1 The Japanese Osteoporosis Drug Market Forecast, 2014-2024
4.8.2 Recent Trends in the Japanese Osteoporosis Drug Market, 2014
4.9 The BRICK Countries Osteoporosis Drug Market, 2013
4.9.1 The BRICK Countries Osteoporosis Drug Market Forecast, 2014-2024
4.9.2 The Chinese Osteoporosis Drug Market Forecast, 2014-2024
4.9.2.1 Main Companies in the Chinese Osteoporosis Drug Market, 2014
4.9.2.2 Growth Drivers in the Chinese Osteoporosis Drug Market, 2014-2024
4.9.3 The Indian Osteoporosis Drug Market Forecast, 2014-2024
4.9.4 The Russian Osteoporosis Drug Market Forecast, 2014-2024
4.9.5 The Brazilian Osteoporosis Drug Market Forecast, 2014-2024
4.9.6 The South Korean Osteoporosis Drug Market Forecast, 2014-2024
4.9.7 The BRICK Countries Osteoporosis Drug Market: Drivers and Restraints, 2014-2024
4.10 The Osteoporosis Drug Market Forecast in the Rest of the World, 2014-2024
4.10.1 Additional Considerations: Challenges for Aging Populations by Region, 2014

5. Global Antiresorptive Drugs Market, 2014-2024
5.1 The Global Antiresorptive Drugs Market Forecast 2014-2024
5.1.1 Breakdown of the Antiresorptive Drugs Market by Drug Category, 2013
5.2 The Global Antiresorptives Drug Market by Drug Category: Sales Forecast 2014-2024
5.3 The Global Bisphosphonates Market, 2013
5.4 The Global Bisphosphonates Drug Market: Sales Forecast 2014-2024
5.5 Breakdown of the Global Bisphosphonates Market: Sales Forecast by Leading Drugs 2014-2024
5.5.1 Actonel/Atelvia (Risedronate)
5.5.1.1 History of Actonel/Atelvia (Risedronate)
5.5.1.2 Generic Competition for Actonel/Atelvia (Risedronate), 2014
5.5.1.3 Actonel/Atelvia (Risedronate) Sales Forecast 2014-2024
5.5.2 Fosamax (Alendronate)
5.5.2.1 History of Fosamax (Alendronate)
5.5.2.2 Generic Competition for Fosamax (Alendronate), 2014
5.5.2.3 Fosamax (Alendronate) Sales Forecast 2014-2024
5.5.3 Reclast/Aclasta (Zoledronic Acid)
5.5.3.1 Reclast/Aclasta (Zoledronic Acid) Strengths and Weaknesses, 2014
5.5.3.2 Reclast/Aclasta (Zoledronic Acid) in the Leading Regional Markets, 2014
5.5.3.3 Generic Competition for Reclast/Aclasta (Zoledronic Acid), 2014
5.5.3.4 Reclast/Aclasta (Zoledronic Acid) Sales Forecast 2014-2024
5.5.4 Boniva (Ibandronate)
5.5.4.1 Boniva (Ibandronate): Sales Forecast 2014-2024
5.6 The Global SERMs Drug Market: Sales Forecast 2014-2024
5.7 Breakdown of the Global SERMs Market: Sales Forecast by Leading Drugs 2014-2024
5.7.1 Evista (Raloxifene)
5.7.1.1 Generic Competition for Evista (Raloxifene), 2014
5.7.1.2 Evista (Raloxifene) Sales Forecast 2014-2024
5.7.2 Duavee/Aprela (Bazedoxifene and Conjugated Estrogens)
5.7.2.1 Duavee/Aprela (Bazedoxifene and Conjugated Estrogens) in the Leading Regional Markets, 2014
5.7.2.2 History of Duavee/Aprela (Bazedoxifene and Conjugated Estrogens)
5.7.2.3 Duavee/Aprela (Bazedoxifene and Conjugated Estrogens) Sales Forecast 2014-2024
5.8 The Global RANKL Antibody Market: Sales Forecast 2014-2024
5.8.1 Prolia (Denosumab)
5.8.1.1 History of Prolia (Denosumab)
5.8.1.2 Prolia to Drive the Market in 2017
5.8.1.3 Safety Profile
5.8.1.4 Prolia: Patent Expiries
5.8.1.5 Prolia (Denosumab) Sales Forecast 2014-2024
5.9 The Global Cathepsin K Inhibitors Market: Sales Forecast 2014-2024
5.9.1 Odanacatib
5.9.1.1 Odanacatib Sales Forecast 2014-2024
5.10 Other Antiresorptive Drugs, 2014
5.10.1 Protelos
5.10.2 Calcitonin-Salmon
5.10.3 Binosto
5.11 Drivers and Restraints for the Global Antiresorptives Drug Market, 2014-2024

6. The Global Anabolic Drugs Market, 2014-2024
6.1 The Global Anabolic Drugs Market, 2013
6.2 The Global Anabolics Drug Market by Drug Category: Sales Forecast 2014-2024
6.3 The Human Recombinant Parathyroid Hormone Peptides Market, 2014
6.3.1 Forteo (Teriparatide) Market: Sales Forecast 2014-2024
6.3.1.1 Forteo Offers a Differentiating Factor in 2014
6.4 The Anti-Sclerostin Market, 2014
6.4.1 Romosozumab: Sales Forecast 2014-2024
6.5 Other Anabolic Drugs
6.5.1 Blosozumab (LY2541546): Second in Class Sclerostin Antibody
6.5.2 ZP-PTH: Parathyroid by Way Micro Needle Patch
6.5.3 ZT-034: Will Need More Than Biomarkers for Approval
6.5.4 Preotact/Preos: Will it be Introduced in the Market Again?
6.5.5 BA-058 (Abaloparatide): Potential Competitor for Forteo
6.5.6 PTH(1-31)NH2: Future Dual-Action Drug

7. Leading Companies in the Osteoporosis Drug Market, 2014
7.1 Leading Companies in the Osteoporosis Drug Market, 2013
7.2 Expected Company Leaders in the OsteoporosisDrug Market in 2024
7.3 Eli Lilly and Co
7.3.1 Eli Lilly Osteoporosis Drug Sales Forecast, 2014-2024
7.4 Amgen
7.4.1 Amgen’s Osteoporosis Product Portfolio
7.4.2 Amgen Osteoporosis Drug Sales Forecast, 2014-2024
7.5 UCB
7.5.1 UCB Osteoporosis Drug Sales Forecast, 2014-2024
7.6 GSK
7.6.1 GSK Osteoporosis Drug Sales Forecast, 2014-2024
7.7 Merck
7.7.1 Merck Osteoporosis Drug Sales Forecast, 2014-2024
7.8 Actavis
7.9 Sanofi
7.10 Pfizer
7.11 Novartis

8. Qualitative Analysis of the Global Osteoporosis Drug Market, 2014-2024
8.1 Pestel Analysis
8.1.1 Political Factors
8.1.2 Economic Factors
8.1.3 Socio-Cultural Factors
8.1.4 Technological Factors
8.1.5 Environmental Factors
8.1.6 Legal Factors
8.2 Porter’s Five Forces Analysis of the Osteoporosis Drugs Market
8.2.1 Competitive Rivalry: High Rivalry Among Competitors
8.2.1.1 Eli Lilly and Amgen Dominate the Biological Osteoporosis Drug Market
8.2.2 Potential Entrants into the Osteoporosis Drug Market: Low Threat of New Entrants
8.2.3 Medium Threat of Substitutes: Who Are The Latent Substitutes?
8.2.4 High Power of Suppliers: Drug Manufacturers Still Have the Power to Lead the Market
8.2.5 High Power of Buyers: Big Pharma to Engulf Smaller Companies
8.3 SWOT Analysis and Strategies
8.3.1 Strengths: Smart Thinking
8.3.2 Weaknesses: Not An Easy Market
8.3.2.1 Patent Expiries
8.3.3 Opportunities: Changing Social Trends
8.3.4 Threats: Highly Stringent but Necessary Regulations
8.3.4.1 Drug Side-Effect Publicity
8.3.4.2 Reimbursement for Bone Metabolism Drugs
8.4 Challenges to Overcome for the Future Osteoporosis Drug Market

9. Expert Opinions
9.1 Interview with Dr. Karl Grindulis, Consultant Rheumatologist at Sandwell General Hospital, West Bromwich, UK
9.1.1 Calcitonin-Salmon in the UK
9.1.2 Personalised Medicine
9.1.3 Expert Views on Romosozumab
9.1.4 Key Factors for the Future
9.2 Interview with Dr. Matthew Drake, Consultant in the Department of Medicine, Division of Endocrinology, Mayo Clinic Rochester, Minnesota, US
9.2.1 Skeletal Anabolic Agents Remain the Biggest Unmet Need
9.2.2 Calcitonin-Salmon: not Recommendable
9.2.3 Shifting to Generics
9.2.4 Romosozumab: Potential Blockbuster
9.2.5 Odanacatib: Intriguing Future Performance
9.2.6 Focusing on Patients with Rare Skeletal Disorders may Give Some Answers

10. Conclusions
10.1 The World Osteoporosis Drug Market by Therapeutic Classes, 2013
10.2 The World Osteoporosis Drug Market Forecast by Drug Category, 2014-2024
10.3 The Global Osteoporosis Drug Market Forecast by Regional Markets, 2014-2024
10.4 The Global Osteoporosis Drug Market Forecast by Leading Drugs, 2014-2024
10.4.1 Leading Companies for the Osteoporosis Drug Market
10.5 Drivers for the Osteoporosis Drugs Market, 2014-2024

List of Tables
Table 1.1 The Global Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Country, 2013-2024
Table 2.1 Mechanisms Involved in Bone Grafting
Table 3.1 Treatments for Osteoporosis, by Therapeutic Classes, Drug Category and Branded Drugs, 2014
Table 3.2 The Global Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 3.3 The Global Osteoporosis Drug Market: Revenue ($bn) and Market Shares (%) by Therapeutic Classes, 2013
Table 3.4 The Global Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Therapeutic Classes, 2013-2024
Table 3.5 The Global Osteoporosis Drug Market: Revenue ($bn) and Market Shares (%) by Leading Drugs, 2013
Table 3.6 Patent Expiry Dates for the Leading Osteoporosis Drugs in US and EU
Table 3.7 The Global Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Leading Drugs, 2013-2024
Table 3.8 The Global Osteoporosis Drug Market: Market Shares (%) by Leading Drugs, 2013, 2018 and 2024
Table 3.9 Osteoporosis Drugs in Development, 2014
Table 4.1 The Global Osteoporosis Drug Market: Revenue ($bn) and Market Shares (%) by Regional Markets, 2013
Table 4.2 The Global Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Regional Market, 2013-2024
Table 4.3 The Global Osteoporosis Drug Market: Market Shares (%) by Leading Regional Markets, 2013, 2018 and 2024
Table 4.4 The US Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 4.5 The EU5 Osteoporosis Drug Market: Revenue ($bn) and Global / Regional Market Shares (%) by Country, 2013
Table 4.6 Median Age in EU5 from 1960 to 2060, by Country
Table 4.7 EU5 Osteoporosis Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Country, 2013-2024
Table 4.8 The German Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 4.9 The French Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 4.10 The UK Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 4.11 The Italian Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 4.12 The Spanish Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 4.13 The Japanese Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 4.14 The BRICK Osteoporosis Drug Market: Revenue ($bn) and Global / Regional Market Shares (%) by Country, 2013
Table 4.15 The BRICK Osteoporosis Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Country, 2013-2024
Table 4.16 The Chinese Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 4.17 The Indian Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 4.18 The Russian Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 4.19 The Brazilian Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 4.20 The South Korean Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 4.21 The ROW Osteoporosis Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 5.1 The Global Antiresorptive Drugs Market: Revenue ($bn) and Market Shares (%) by Drug Category, 2013
Table 5.2 The Global Antiresorptives Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Drug Category, 2013-2024
Table 5.3 The Global Bisphosphonates Drug Market: Revenue ($bn) and Market Shares (%) by Leading Drugs, 2013
Table 5.4 The Global Bisphosphonates Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%),2013-2024
Table 5.5 The Global Bisphosphonates Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Leading Drugs, 2013-2024
Table 5.6 Actonel / Atelvia: Sales ($bn) and Market Shares (%) by Company, 2013
Table 5.7 Actonel / Atelvia Revenue Forecast: Revenue ($bn), AGR (%) and CAGR (%),2013-2024
Table 5.8 Fosamax Revenue Forecast: Revenue ($bn), AGR (%) and CAGR (%),2013-2024
Table 5.9 Reclast/Aclasta Revenue Forecast: Revenue ($bn), AGR (%) and CAGR (%),2013-2024
Table 5.10 Boniva Revenue Forecast: Revenue ($bn), AGR (%) and CAGR (%),2013-2024
Table 5.11 The Global SERMs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%),2013-2024
Table 5.12 The Global SERMs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Leading Drugs, 2013-2024
Table 5.13 Evista Revenue Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 5.14 Duavee Revenue Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 5.15 Prolia: Sales ($bn) and Market Shares (%) by Company, 2013
Table 5.16 Prolia Revenue Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 5.17 Odanacatib Revenue Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 6.1 The Global Anabolic Drug Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Drug Category, 2013-2024
Table 6.2 Hormones Involved in Bone Metabolism
Table 6.3 Forteo Revenue Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 6.4 Romosozumab Revenue Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2013-2024
Table 7.1 Leading Companies for the Global Osteoporosis Drug Market: Revenue ($bn), Drug Market Shares (%) and Company Market Shares (%) by Leading Drugs, 2013
Table 7.2 Forecasts for the Leading Companies in the Global Osteoporosis Drug Market: Revenue ($bn), Drug Market Shares (%) and Company Market Shares (%) by Leading Drugs, 2024
Table 7.3 Eli Lilly Osteoporosis Drug Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Leading Drugs, 2013-2024
Table 7.4 Prolia Patents Expiration Dates
Table 7.5 Amgen Osteoporosis Drug Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Leading Drugs, 2013-2024
Table 7.6 UCB Osteoporosis Drug Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Leading Drug, 2013-2024
Table 7.7 GSK Osteoporosis Drug Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Leading Drugs, 2013-2024
Table 7.8 Merck Osteoporosis Drug Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%)by Leading Drugs, 2013-2024
Table 7.9 Actavis Osteoporosis Drug Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Leading Drug, 2013-2024
Table 7.10 Sanofi Osteoporosis Drug Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Leading Drug, 2013-2024
Table 10.1 Segmentation of the Osteoporosis Drug Market, 2014

List of Figures
Figure 1.2 Global Osteoporosis Drug Market Segmentation
Figure 3.1 The Global Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 3.2 The Global Osteoporosis Drug Market: Revenue ($bn) by Therapeutic Classes, 2013
Figure 3.3 The Global Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%) by Therapeutic Classes, 2013-2024
Figure 3.4 The Global Osteoporosis Drug Market: Revenue ($bn) by Leading Drugs, 2013
Figure 3.5 The Global Osteoporosis Drug Market Forecast: Revenue ($bn) by Leading Drugs, 2013-2024
Figure 3.6 The Global Osteoporosis Drug Market: Market Shares (%) by Leading Drugs, 2013
Figure 3.7 The Global Osteoporosis Drug Market: Market Shares (%) by Leading Drugs, 2018
Figure 3.8 The Global Osteoporosis Drug Market: Market Shares (%) by Leading Drugs, 2024
Figure 3.9 Historic and Projected Timeline for the Osteoporosis Drug Market, 2014
Figure 3.10 The Global Osteoporosis Drug Market: Drivers and Restraints, 2014-2024
Figure 4.1 The Global Osteoporosis Drug Market: Revenue ($bn) by Regional Markets, 2013
Figure 4.2 The Global Osteoporosis Drug Market Forecast: Revenue ($bn) by Regional Markets, 2013-2024
Figure 4.3 The Global Osteoporosis Drug Market: Market Shares (%) by Leading Regional Markets, 2013
Figure 4.4 Global Osteoporosis Drug Market: Market Shares (%) by Leading Regional Markets, 2018
Figure 4.5 Global Osteoporosis Drug Market: Market Shares (%) by Leading Regional Markets, 2024
Figure 4.6 The US Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 4.7 The US Osteoporosis Drug Market: Drivers and Restraints, 2014-2024
Figure 4.8 The EU5 Osteoporosis Drug Market: Global Revenues ($bn) by Country, 2013
Figure 4.9 EU5 Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%) by Country, 2013-2024
Figure 4.10 The German Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 4.11The French Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 4.12 The UK Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 4.13 The Italian Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 4.14 The Spanish Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 4.15 The Japanese Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 4.16 The BRICK Osteoporosis Drug Market: Global Revenues ($bn) by Country, 2013
Figure 4.17 The BRICK Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%) by Country, 2013-2024
Figure 4.18 The Chinese Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 4.19 The Indian Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 4.20 The Russian Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 4.21 The Brazilian Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 4.22 The South Korean Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 4.23 The BRICK Countries Osteoporosis Drug Market: Drivers and Restraints, 2014-2024
Figure 4.24 The ROW Osteoporosis Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 5.1 The Global Antiresorptive Drugs Market Within the Osteoporosis Drug Market: Market Shares (%) by Therapeutic Classes and by Drug Category, 2013
Figure 5.2 The Global Antiresorptives Drug Market Forecast: Revenue ($bn) and AGR (%) by Drug Category, 2013-2024
Figure 5.3 The Global Bisphosphonates Market: Market Share (%) by Leading Drugs, 2013
Figure 5.4 The Global Bisphosphonates Drug Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 5.5 The Global Bisphosphonates Drug Market Forecast: Revenue ($bn) by Leading Drugs, 2013-2024
Figure 5.6 Actonel / Atelvia Revenue Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 5.7 Fosamax Revenue Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 5.8 Reclast/Aclasta Revenue Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 5.9 Boniva Revenue Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 5.10 The Global SERMs Market Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 5.11 The Global SERMs Market Forecast: Revenue ($bn) by Leading Drugs, 2013-2024
Figure 5.12 Evista Revenue Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 5.13 Duavee Revenue Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 5.14 Prolia Revenue Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 5.15 Odanacatib Revenue Forecast: Revenue ($bn) and AGR (%), 2013-2024
Figure 5.16 The Global Antiresorptive Drug Market: Drivers and Restraints, 2014-2024
Figure 6.1 The Global Anabolic Drug Market Forecast: Revenue ($bn) and AGR (%) by Drug Category, 2013-2024
Figure 6.2 Forteo Revenue Forecast: Revenue ($bn) and AGR (%),2013-2024
Figure 6.3 Romosozumab Revenue Forecast: Revenue ($bn) and AGR (%),2013-2024
Figure 7.1 Market Shares (%) of the Leading Companies for the Global Osteoporosis Drug Market, 2013
Figure 7.2 Market Shares (%) of the Leading Companies for the Global Osteoporosis Drug Market, 2024
Figure 7.3 Eli Lilly Osteoporosis Drug Sales Forecast: Revenue ($bn) and AGR (%) by Leading Drugs, 2013-2024
Figure 7.4 Amgen Osteoporosis Drug Sales Forecast: Revenue ($bn) and AGR (%) by Leading Drugs, 2013-2024
Figure 7.5 UCB Osteoporosis Drug Sales Forecast: Revenue ($bn) and AGR (%) by Leading Drugs, 2013-2024
Figure 7.6 GSK Osteoporosis Drug Sales Forecast: Revenue ($bn) and AGR (%) by Leading Drugs, 2013-2024
Figure 7.7 Merck Osteoporosis Drug Sales Forecast: Revenue ($bn) and AGR (%) by Leading Drugs, 2013-2024
Figure 7.8 Actavis Osteoporosis Drug Sales Forecast: Revenue ($bn) and AGR (%) by Leading Drug, 2013-2024
Figure 7.9 Sanofi Osteoporosis Drug Sales Forecast: Revenue ($bn) and AGR (%) by Leading Drug, 2013-2024
Figure 8.1 Porter’s Five Forces Analysis of the Osteoporosis Drug Market, 2014-2024
Figure 10.1 The Global Osteoporosis Drug Market Shares (%) by Therapeutic Class, 2013
Figure 10.2 The Global Osteoporosis Drug Market Forecast: Revenue ($bn) by Drug Categories, 2013-2024
Figure 10.3 The Global Osteoporosis Drug Market Forecast: Revenue ($bn) by Regional Market, 2013-2024
Figure 10.4 The Global Osteoporosis Drug Market Forecast: Revenue ($bn) by Leading Drugs, 2013-2024

【レポートのキーワード】

骨粗しょう症治療薬、再吸収阻害薬、同化薬

★調査レポート[世界の骨粗しょう症治療・予防市場予測:抗嘔吐薬、骨粗しょう症治療薬、再吸収阻害薬、同化薬] ( Osteoporosis Treatment and Prevention: World Drug Market Forecast 2014-2024 & Future Prospects for Leading Companies / VISG409054) 販売に関する免責事項
[世界の骨粗しょう症治療・予防市場予測:抗嘔吐薬、骨粗しょう症治療薬、再吸収阻害薬、同化薬] ( Osteoporosis Treatment and Prevention: World Drug Market Forecast 2014-2024 & Future Prospects for Leading Companies / VISG409054) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆